Screener
Indivior Pharmaceuticals, Inc. INDV Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock | — | 1 |
| Cash paid for repurchases of common stock | (126) | (11) |
| Proceeds from debt, net | 489 | — |
| Repayments of debt | (333) | (4) |
| Transaction costs related to debt refinancing | (5) | — |
| Settlement of equity awards | (21) | (3) |
| Other | 3 | — |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s debt issuance proceeds?
- Indivior Pharmaceuticals, Inc. (INDV) reported debt issuance proceeds of $489M in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Indivior Pharmaceuticals, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude